The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SRRK | +42.46% | -5.63% | -1.15% | +156% |
| S&P | +12.26% | +86.71% | +13.3% | +144% |
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
The biotech suffered a regulatory setback last month, and this new development might be another blow to its prospects.
A pundit at an influential U.S. bank is quite bullish on the company's future.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.42M | 5.2% |
| Market Cap | $3.58B | 458.4% |
| Market Cap / Employee | $18.26M | 0.0% |
| Employees | 196 | 30.7% |
| Net Income | -$102.22M | -58.5% |
| EBITDA | -$103.13M | -60.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $286.77M | 275.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $104.75M | 73.0% |
| Short Term Debt | $5.33M | -11.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -119.63% | -14.5% |
| Return On Invested Capital | -48.29% | -2.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$69.01M | -31.5% |
| Operating Free Cash Flow | -$68.92M | -31.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 43.70 | 8.18 | 10.76 | 15.32 | 89.20% |
| Price to Tangible Book Value | 43.70 | 8.18 | 10.76 | 15.32 | 89.20% |
| Enterprise Value to EBITDA | -53.40 | -42.95 | -33.65 | -38.55 | 251.84% |
| Return on Equity | -82.9% | -106.7% | -172.1% | -218.0% | 19.10% |
| Total Debt | $65.13M | $63.14M | $61.53M | $110.08M | 65.26% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
